Beyond Therapeutics Co., Ltd., a biotechnology company based in Suzhou with a focus on ophthalmology and oncology, has reportedly raised tens of millions of renminbi in a Pre-Series A financing round. The round was led by Ming Bioventures, with contributions from Highpower Industrial and 3D BioOptima. The funds will be allocated to accelerate pre-clinical regulatory filings in the US and China, as well as to enhance the Experiment + Computation w/ Enhanced Evaluation & DMPK (ExCEED) technology platform.
Company Background and Pipeline Highlights
Founded in 2021, Beyond Therapeutics has made significant strides with its pipeline, notably with BT01001, a small molecule eye drop product targeting fundus diseases. BT01001 has demonstrated excellent preclinical data, showing high target selectivity and sufficient exposure to fundus target tissues. The drug’s efficacy and safety data across multiple animal species have shown significant advantages over macromolecules, addressing patient compliance issues and poor drug accessibility associated with invasive administration methods.
BT01002: A Promising Small Molecule Inhibitor for High-Risk Leukemia
Another drug candidate in development is BT01002, a small molecule inhibitor aimed at treating a subtype of high-risk leukemia that is prone to relapse and is difficult to treat. Preclinical data indicates that BT01002 has no risk of QTc prolongation and enhances the metabolic stability of the human body. This target is directly involved in signal transduction in multiple types of tumors, suggesting that its potential indications could extend to various solid tumors.-Fineline Info & Tech
